Pancreatic Cancer Research

ResearcherWashington University in St. LouisActive in the last 2 years

Benjamin R. Tan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1838-1182; OpenAlex author ID A5050288292. Sources: ClinicalTrials.gov.

Their work

Papers
13 (first author 1, last author 0)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
0
Collaborators
44
Papers, trials and grants by year

2002: 1 trial · 2003: none · 2004: none · 2005: none · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: 1 paper · 2012: 1 paper · 2013: 2 papers, 1 trial · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 4 papers · 2024: none · 2025: 1 paper

Papers 13

  1. Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-24-1821↗
  2. MR-Guided Radiation Therapy With Concurrent Gemcitabine/Nab-Paclitaxel Chemotherapy in Inoperable Pancreatic Cancer: A TITE-CRM Phase I Trial. Co-author DOI 10.1016/j.ijrobp.2022.07.015↗
  3. Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma. First author DOI 10.1093/oncolo/oyac237↗
  4. A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy. Co-author DOI 10.1158/1078-0432.ccr-23-1405↗
  5. Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansio… Co-author DOI 10.1158/1078-0432.ccr-23-2993↗
  6. Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study. Co-author DOI 10.1158/1078-0432.ccr-22-0308↗
  7. Phase Ib/II study combining tosedostat with capecitabine in patients with advanced pancreatic adenocarcinoma. Co-author DOI 10.21037/jgo.2019.11.06↗
  8. Interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: long-term follow-up. Co-author DOI 10.1016/j.hpb.2017.01.012↗
  9. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancrea… Co-author DOI 10.1016/s1470-2045(16)00078-4↗
  10. A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma. Co-author DOI 10.1007/s10637-012-9866-y↗
  11. Vitamin D deficiency and prognostics among patients with pancreatic adenocarcinoma. Co-author DOI 10.1186/1479-5876-11-206↗
  12. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. Co-author DOI 10.6092/1590-8577/913↗
  13. A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B… Co-author DOI 10.1002/cncr.25742↗

Trials 2

  1. VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors Principal investigator NCT01784861↗
  2. A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers Principal investigator NCT00660699↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andrea Wang‐Gillam · 11 shared papers, 2012–2025 · strength 1.13
  2. Kian‐Huat Lim · 8 shared papers, 2016–2025 · strength 1.04
  3. Katrina Sophia Pedersen · 7 shared papers, 2020–2025 · strength 0.99
  4. Patrick M. Grierson · 4 shared papers, 2020–2025 · strength 0.61
  5. William G. Hawkins · 6 shared papers, 2013–2023 · strength 0.53
  6. Albert Craig Lockhart · 7 shared papers, 2012–2023 · strength 0.48
  7. David G DeNardo · 4 shared papers, 2016–2025 · strength 0.48
  8. Feng Gao · 3 shared papers, 2012–2023 · strength 0.27
  9. Robert R. McWilliams · 3 shared papers, 2012–2023 · strength 0.27
  10. Ryan C Fields · 3 shared papers, 2016–2023 · strength 0.25
  11. Brett H. Herzog · 2 shared papers, 2022–2023 · strength 0.24
  12. Jad I. Belle · 2 shared papers, 2022–2023 · strength 0.24
  13. John M. Baer · 1 shared paper, 2025 · strength 0.19
  14. Sapana Bansod · 1 shared paper, 2023 · strength 0.16
  15. Channing J. Der · 1 shared paper, 2023 · strength 0.16
  16. David C. Linehan · 3 shared papers, 2012–2017 · strength 0.14
  17. Michael Charles Roach · 1 shared paper, 2023 · strength 0.14
  18. Todd A. DeWees · 1 shared paper, 2023 · strength 0.14
  19. Hyun Jee Kim · 1 shared paper, 2023 · strength 0.14
  20. Lauren E. Henke · 1 shared paper, 2023 · strength 0.14
  21. Parag Jitendra Parikh · 1 shared paper, 2023 · strength 0.14
  22. Shahed Nicolas Badiyan · 1 shared paper, 2023 · strength 0.14
  23. Chet W. Hammill · 1 shared paper, 2023 · strength 0.14
  24. Steven M. Strasberg · 2 shared papers, 2016–2017 · strength 0.12
  25. Andrea S. Teague · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.